233 related articles for article (PubMed ID: 22760779)
1. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation.
Brennan TV; Lin L; Huang X; Cardona DM; Li Z; Dredge K; Chao NJ; Yang Y
Blood; 2012 Oct; 120(14):2899-908. PubMed ID: 22760779
[TBL] [Abstract][Full Text] [Related]
2. α-1 antitrysin DAMPens GVHD.
Reddy P
Blood; 2012 Oct; 120(14):2780-1. PubMed ID: 23043026
[TBL] [Abstract][Full Text] [Related]
3. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation.
Choi SW; Hildebrandt GC; Olkiewicz KM; Hanauer DA; Chaudhary MN; Silva IA; Rogers CE; Deurloo DT; Fisher JM; Liu C; Adams D; Chensue SW; Cooke KR
Blood; 2007 Nov; 110(9):3447-55. PubMed ID: 17641205
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
[TBL] [Abstract][Full Text] [Related]
7. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
[TBL] [Abstract][Full Text] [Related]
8. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
Shono Y; Docampo MD; Peled JU; Perobelli SM; Velardi E; Tsai JJ; Slingerland AE; Smith OM; Young LF; Gupta J; Lieberman SR; Jay HV; Ahr KF; Porosnicu Rodriguez KA; Xu K; Calarfiore M; Poeck H; Caballero S; Devlin SM; Rapaport F; Dudakov JA; Hanash AM; Gyurkocza B; Murphy GF; Gomes C; Liu C; Moss EL; Falconer SB; Bhatt AS; Taur Y; Pamer EG; van den Brink MRM; Jenq RR
Sci Transl Med; 2016 May; 8(339):339ra71. PubMed ID: 27194729
[TBL] [Abstract][Full Text] [Related]
9. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
10. The central nervous system is a target of acute graft versus host disease in mice.
Hartrampf S; Dudakov JA; Johnson LK; Smith OM; Tsai J; Singer NV; West ML; Hanash AM; Albert MH; Liu B; Toth M; van den Brink MR
Blood; 2013 Mar; 121(10):1906-10. PubMed ID: 23299314
[TBL] [Abstract][Full Text] [Related]
11. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
[TBL] [Abstract][Full Text] [Related]
12. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
14. A critical role for donor-derived IL-22 in cutaneous chronic GVHD.
Gartlan KH; Bommiasamy H; Paz K; Wilkinson AN; Owen M; Reichenbach DK; Banovic T; Wehner K; Buchanan F; Varelias A; Kuns RD; Chang K; Fedoriw Y; Shea T; Coghill J; Zaiken M; Plank MW; Foster PS; Clouston AD; Blazar BR; Serody JS; Hill GR
Am J Transplant; 2018 Apr; 18(4):810-820. PubMed ID: 28941323
[TBL] [Abstract][Full Text] [Related]
15. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
[TBL] [Abstract][Full Text] [Related]
16. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
17. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.
Tawara I; Sun Y; Lewis EC; Toubai T; Evers R; Nieves E; Azam T; Dinarello CA; Reddy P
Proc Natl Acad Sci U S A; 2012 Jan; 109(2):564-9. PubMed ID: 22203983
[TBL] [Abstract][Full Text] [Related]
19. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
20. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
